Akebia Therapeutics (AKBA) EBIAT: 2016-2025
Historic EBIAT for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $540,000.
- Akebia Therapeutics' EBIAT rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
- According to the latest figures from Q3 2025, Akebia Therapeutics' EBIAT is $540,000, which was up 118.62% from $247,000 recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' EBIAT ranged from a high of $29.4 million in Q2 2022 and a low of -$83.0 million during Q2 2021.
- Over the past 3 years, Akebia Therapeutics' median EBIAT value was -$11.2 million (recorded in 2023), while the average stood at -$10.4 million.
- Per our database at Business Quant, Akebia Therapeutics' EBIAT skyrocketed by 135.46% in 2022 and then plummeted by 3,814.01% in 2024.
- Akebia Therapeutics' EBIAT (Quarterly) stood at -$69.9 million in 2021, then spiked by 91.31% to -$6.1 million in 2022, then skyrocketed by 110.11% to $614,000 in 2023, then slumped by 3,814.01% to -$22.8 million in 2024, then soared by 102.69% to $540,000 in 2025.
- Its EBIAT stands at $540,000 for Q3 2025, versus $247,000 for Q2 2025 and $6.1 million for Q1 2025.